Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Merck downgraded to Neutral from Buy at Citi » 05:29
11/29/21
11/29
05:29
11/29/21
05:29
MRK

Merck

$78.65 /

-3.65 (-4.43%)

Citi analyst Andrew Baum…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$78.65 /

-3.65 (-4.43%)

MRK Merck
$78.65 /

-3.65 (-4.43%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
MRK Merck
$78.65 /

-3.65 (-4.43%)

MRK Merck
$78.65 /

-3.65 (-4.43%)

MRK Merck
$78.65 /

-3.65 (-4.43%)

MRK Merck
$78.65 /

-3.65 (-4.43%)

Friday
On The Fly
Wall Street in Fives - Must Read Lists for Friday » 13:21
11/26/21
11/26
13:21
11/26/21
13:21
MRNA

Moderna

$332.27 /

+59 (+21.59%)

, PFE

Pfizer

$54.12 /

+3.22 (+6.33%)

, MRK

Merck

$78.24 /

-4.06 (-4.93%)

, BNTX

BioNTech

$353.00 /

+47.71 (+15.63%)

, OCGN

Ocugen

$6.47 /

-0.62 (-8.74%)

, AAPL

Apple

$157.52 /

-4.47 (-2.76%)

, ZM

Zoom Video

$220.65 /

+12.41 (+5.96%)

, PTON

Peloton

$46.33 /

+2.44 (+5.56%)

, AAL

American Airlines

$17.49 /

-1.97 (-10.12%)

, UAL

United Airlines

$42.44 /

-4.29 (-9.18%)

, DAL

Delta Air Lines

$36.20 /

-3.48 (-8.77%)

, CCL

Carnival

$17.98 /

-2.175 (-10.79%)

, NCLH

Norwegian Cruise Line

$20.22 /

-2.4 (-10.61%)

, RCL

Royal Caribbean

$68.14 /

-10.21 (-13.03%)

, PDD

Pinduoduo

$68.52 /

-12.85 (-15.79%)

, DIDI

Didi

$7.87 /

-0.24 (-2.96%)

, QSR

Restaurant Brands

$57.95 /

-0.815 (-1.39%)

, AMZN

Amazon.com

$3,509.00 /

-70.75 (-1.98%)

, HUBS

HubSpot

$806.16 /

+3.9899 (+0.50%)

, TSLA

Tesla

$1,082.15 /

-33.85 (-3.03%)

, BABA

Alibaba

$133.30 /

-3.32 (-2.43%)

, QGEN

Qiagen

$56.42 /

+1.81 (+3.31%)

, LIAN

LianBio

$16.06 /

+0.49 (+3.15%)

, NVO

Novo Nordisk

$108.19 /

-0.775 (-0.71%)

, CANF

Can-Fite BioPharma

$1.23 /

+0.05 (+4.24%)

, UK

Ucommune International

/

+

, MLCO

Melco Resorts & Entertainment

$10.39 /

-1.225 (-10.55%)

, SCHYY

Sands China

$26.54 /

+0.84 (+3.27%)

, SJMHY

SJM Holdings

$3.09 /

+ (+0.00%)

, WYNMF

Wynn Macau

/

+

, GXYEF

Galaxy Entertainment

$6.14 /

+ (+0.00%)

, MDEVF

Melco International

$1.40 /

+ (+0.00%)

, MCHVF

MGM China

/

+

, MSC

Studio City

$6.66 /

-0.57 (-7.88%)

, PBR

Petrobras

$10.48 /

+ (+0.00%)

, BP

BP

$25.83 /

-1.82 (-6.58%)

, CVX

Chevron

$114.26 /

-2.94 (-2.51%)

, COP

ConocoPhillips

$71.45 /

-3.39 (-4.53%)

, XOM

Exxon Mobil

$61.17 /

-2.3 (-3.62%)

, RDS.A

Royal Dutch Shell

$42.06 /

-2.16 (-4.88%)

, TOT

TotalEnergies

/

+

Get caught up quickly on…

ShowHide Related Items >><<
ZM Zoom Video
$220.65 /

+12.41 (+5.96%)

XOM Exxon Mobil
$61.17 /

-2.3 (-3.62%)

UK Ucommune International
/

+

UAL United Airlines
$42.44 /

-4.29 (-9.18%)

TSLA Tesla
$1,082.15 /

-33.85 (-3.03%)

TOT TotalEnergies
/

+

RDS.A Royal Dutch Shell
$42.06 /

-2.16 (-4.88%)

RCL Royal Caribbean
$68.14 /

-10.21 (-13.03%)

QSR Restaurant Brands
$57.95 /

-0.815 (-1.39%)

QGEN Qiagen
$56.42 /

+1.81 (+3.31%)

PTON Peloton
$46.33 /

+2.44 (+5.56%)

PFE Pfizer
$54.12 /

+3.22 (+6.33%)

PDD Pinduoduo
$68.52 /

-12.85 (-15.79%)

PBR Petrobras
$10.48 /

+ (+0.00%)

OCGN Ocugen
$6.47 /

-0.62 (-8.74%)

NVO Novo Nordisk
$108.19 /

-0.775 (-0.71%)

NCLH Norwegian Cruise Line
$20.22 /

-2.4 (-10.61%)

MSC Studio City
$6.66 /

-0.57 (-7.88%)

MRNA Moderna
$332.27 /

+59 (+21.59%)

MRK Merck
$78.24 /

-4.06 (-4.93%)

MLCO Melco Resorts & Entertainment
$10.39 /

-1.225 (-10.55%)

HUBS HubSpot
$806.16 /

+3.9899 (+0.50%)

DIDI Didi
$7.87 /

-0.24 (-2.96%)

DAL Delta Air Lines
$36.20 /

-3.48 (-8.77%)

CVX Chevron
$114.26 /

-2.94 (-2.51%)

COP ConocoPhillips
$71.45 /

-3.39 (-4.53%)

CCL Carnival
$17.98 /

-2.175 (-10.79%)

CANF Can-Fite BioPharma
$1.23 /

+0.05 (+4.24%)

BP BP
$25.83 /

-1.82 (-6.58%)

BNTX BioNTech
$353.00 /

+47.71 (+15.63%)

BABA Alibaba
$133.30 /

-3.32 (-2.43%)

AMZN Amazon.com
$3,509.00 /

-70.75 (-1.98%)

AAPL Apple
$157.52 /

-4.47 (-2.76%)

AAL American Airlines
$17.49 /

-1.97 (-10.12%)

MRNA Moderna
$332.27 /

+59 (+21.59%)

11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
PFE Pfizer
$54.12 /

+3.22 (+6.33%)

11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
11/26/21 Mizuho
Pfizer data on vupanorsen is mixed, says Mizuho
11/24/21 Truist
Pfizer price target raised to $58 from $43 at Truist
11/24/21 Oppenheimer
Enanta price target raised to $73 from $55 at Oppenheimer
MRK Merck
$78.24 /

-4.06 (-4.93%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
BNTX BioNTech
$353.00 /

+47.71 (+15.63%)

11/10/21
Fly Intel: Top five analyst upgrades
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/10/21 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
10/22/21
Fly Intel: Top five analyst initiations
OCGN Ocugen
$6.47 /

-0.62 (-8.74%)

07/26/21 Noble Capital
Ocugen initiated with an Outperform at Noble Capital
07/06/21 Roth Capital
Covaxin data continue to meet FDA efficacy threshold, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
AAPL Apple
$157.52 /

-4.47 (-2.76%)

11/26/21 Wedbush
Wedbush sees Apple on pace to sell over 10M iPhones over Black Friday weekend
11/26/21
Apple to launch AR headset in 2022, TFI Asset's Kuo predicts
11/24/21 UBS
Apple demand remains strong, supply constraints improving, says UBS
11/23/21 Wells Fargo
China October mobile phone data positive for Apple, says Wells Fargo
ZM Zoom Video
$220.65 /

+12.41 (+5.96%)

11/23/21
Fly Intel: Top five analyst downgrades
11/23/21 BofA
Zoom Video downgraded to Neutral from Buy at BofA
11/23/21 Wells Fargo
Zoom Video price target lowered to $245 from $275 at Wells Fargo
11/23/21 Evercore ISI
Zoom Video price target lowered to $235 from $255 at Evercore ISI
PTON Peloton
$46.33 /

+2.44 (+5.56%)

11/16/21 Baird
Baird adds Peloton as 'Fresh Pick,' says capital raise removes overhang
11/16/21 BMO Capital
Peloton 'backpedaling again' with $1B offering, says BMO Capital
11/11/21 RBC Capital
Affirm price target raised to $175 from $130 at RBC Capital
11/09/21 JMP Securities
Peloton should be bought on weakness, says JMP Securities
AAL American Airlines
$17.49 /

-1.97 (-10.12%)

10/06/21
Fly Intel: Top five analyst downgrades
10/06/21 Goldman Sachs
American Airlines downgraded to Sell from Neutral at Goldman Sachs
08/11/21 Redburn
American Airlines initiated with a Buy at Redburn
07/27/21
Fly Intel: Top five analyst upgrades
UAL United Airlines
$42.44 /

-4.29 (-9.18%)

10/21/21 Cowen
United Airlines price target raised to $78 from $72 at Cowen
08/11/21 Redburn
United Airlines initiated with a Sell at Redburn
07/22/21 MKM Partners
United Airlines price target lowered to $61 from $65 at MKM Partners
07/22/21 Susquehanna
United Airlines price target lowered to $51 from $56 at Susquehanna
DAL Delta Air Lines
$36.20 /

-3.48 (-8.77%)

11/19/21 Wolfe Research
Delta Air Lines upgraded to Outperform from Peer Perform at Wolfe Research
10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
10/14/21 Cowen
Delta Air Lines price target raised to $54 from $53 at Cowen
10/14/21 Morgan Stanley
Delta Air Lines price target lowered to $62 from $67 at Morgan Stanley
CCL Carnival
$17.98 /

-2.175 (-10.79%)

10/25/21
Fly Intel: Top five analyst downgrades
10/25/21 Citi
Citi downgrades Carnival to Neutral, sees more upside in Norwegian
10/25/21 Citi
Carnival downgraded to Neutral from Buy at Citi
10/21/21
Fly Intel: Top five analyst upgrades
NCLH Norwegian Cruise Line
$20.22 /

-2.4 (-10.61%)

11/16/21 Stifel
Norwegian Cruise Line weakness a buying opportunity, says Stifel
11/11/21 Berenberg
Norwegian Cruise Line price target raised to $27 from $25 at Berenberg
11/05/21 Deutsche Bank
Norwegian Cruise Line price target raised to $28 from $26 at Deutsche Bank
11/04/21 Wedbush
Norwegian Cruise Line price target raised to $35 from $30 at Wedbush
RCL Royal Caribbean
$68.14 /

-10.21 (-13.03%)

11/01/21 Deutsche Bank
Royal Caribbean price target lowered to $81 from $83 at Deutsche Bank
09/24/21 Stifel
Royal Caribbean price target raised to $111 from $95 at Stifel
09/22/21 Truist
Royal Caribbean price target raised to $80 from $72 at Truist
08/23/21 William Blair
Royal Caribbean estimates lowered on marketing ramp-up at William Blair
PDD Pinduoduo
$68.52 /

-12.85 (-15.79%)

11/02/21 Barclays
Pinduoduo initiated with Equal Weight, $103 target at Barclays
11/02/21 Barclays
Pinduoduo initiated with an Equal Weight at Barclays
08/25/21 BofA
Pinduoduo price target raised to $148 from $143 at BofA
08/25/21 Benchmark
Pinduoduo price target lowered to $156 from $176 at Benchmark
DIDI Didi
$7.87 /

-0.24 (-2.96%)

07/28/21 Alliance Global Partners
Alliance Global Partners bullish on Aurora Mobile despite regulatory changes
07/28/21 Alliance Global Partners
iClick Interactive price target lowered to $15 from $21 at Alliance Global
07/26/21 Atlantic Equities
Atlantic Equities downgrades DiDi to Neutral amid active investigations
07/26/21 Atlantic Equities
DiDi downgraded to Neutral from Overweight at Atlantic Equities
QSR Restaurant Brands
$57.95 /

-0.815 (-1.39%)

11/11/21
Fly Intel: Top five analyst downgrades
11/11/21 KeyBanc
Restaurant Brands downgraded to Sector Weight from Overweight at KeyBanc
10/27/21
Fly Intel: Top five analyst downgrades
10/27/21 Argus
Restaurant Brands downgraded to Hold at Argus on cost pressure, labor shortage
AMZN Amazon.com
$3,509.00 /

-70.75 (-1.98%)

11/24/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
11/22/21 Guggenheim
Amazon.com assumed with a Buy at Guggenheim
11/19/21 RBC Capital
Williams-Sonoma price target raised to $219 from $199 at RBC Capital
11/18/21 Bernstein
Amazon card news in the U.K. 'clearly a show of strength,' says Bernstein
HUBS HubSpot
$806.16 /

+3.9899 (+0.50%)

11/19/21 Argus
HubSpot price target raised to $970 from $930 at Argus
11/04/21 Canaccord
HubSpot price target raised to $845 from $830 at Canaccord
11/04/21 Raymond James
HubSpot price target raised to $900 from $800 at Raymond James
11/04/21 Wells Fargo
HubSpot price target raised to $860 from $835 at Wells Fargo
TSLA Tesla
$1,082.15 /

-33.85 (-3.03%)

11/24/21 Morgan Stanley
Morgan Stanley stays Underweight Ford, admits to being wrong after near-double
11/19/21 Morgan Stanley
Apple Car would be 'ultimate EV bear case,' says Morgan Stanley
11/19/21 Wedbush
Tesla price target raised to $1,400 from $1,100 at Wedbush
11/17/21 Exane BNP Paribas
Exane BNP Paribas boosts Tesla target to $780, keeps Underpeform rating
BABA Alibaba
$133.30 /

-3.32 (-2.43%)

11/24/21
Fly Intel: Top five analyst downgrades
11/24/21 Argus
Alibaba downgraded to Hold from Buy at Argus
11/23/21 Needham
Alibaba price target lowered to $230 from $330 at Needham
11/19/21 Benchmark
Alibaba price target lowered to $245 from $270 at Benchmark
QGEN Qiagen
$56.42 /

+1.81 (+3.31%)

10/14/21 Cowen
Qiagen coverage transferred at Cowen
10/14/21 Redburn
Qiagen initiated with a Buy at Redburn
07/14/21 Citi
Qiagen price target lowered to $58 from $65 at Citi
07/14/21 Kepler Cheuvreux
Qiagen downgraded to Hold from Buy at Kepler Cheuvreux
LIAN LianBio
$16.06 /

+0.49 (+3.15%)

11/26/21 BofA
LianBio initiated with a Buy at BofA
11/26/21 Goldman Sachs
LianBio initiated with a Neutral at Goldman Sachs
11/26/21 Jefferies
LianBio initiated with a Buy at Jefferies
11/24/21 Raymond James
LianBio initiated with an Outperform at Raymond James
NVO Novo Nordisk
$108.19 /

-0.775 (-0.71%)

11/19/21 RBC Capital
Dicerna downgraded to Sector Perform from Outperform at RBC Capital
11/11/21 UBS
Novo Nordisk price target raised to DKK 725 from DKK 630 at UBS
11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
CANF Can-Fite BioPharma
$1.23 /

+0.05 (+4.24%)

06/15/21 Alliance Global Partners
Can-Fite BioPharma initiated with a Buy at Alliance Global Partners
UK Ucommune International
/

+

MLCO Melco Resorts & Entertainment
$10.39 /

-1.225 (-10.55%)

11/26/21 Credit Suisse
Credit Suisse upgrades Macau stocks with 'light at the end of the tunnel'
11/24/21 Credit Suisse
Melco Resorts upgraded to Outperform from Underperform at Credit Suisse
09/28/21 Citi
Melco Resorts price target lowered to $14.50 from $24.50 at Citi
09/24/21 Credit Suisse
As Macau locks down, Credit Suisse warns of downside risk to 2022 GGR estimates
SCHYY Sands China
$26.54 /

+0.84 (+3.27%)

11/24/21 Credit Suisse
Sands China upgraded to Outperform from Neutral at Credit Suisse
11/19/21 JPMorgan
Sands China upgraded to Neutral from Underweight at JPMorgan
09/15/21 JPMorgan
Sands China downgraded to Underweight from Overweight at JPMorgan
SJMHY SJM Holdings
$3.09 /

+ (+0.00%)

11/24/21 Credit Suisse
SJM Holdings upgraded to Outperform from Neutral at Credit Suisse
09/15/21 JPMorgan
SJM Holdings downgraded to Neutral from Overweight at JPMorgan
02/08/21 JPMorgan
SJM Holdings upgraded to Overweight from Neutral at JPMorgan
WYNMF Wynn Macau
/

+

11/24/21 Credit Suisse
Wynn Macau upgraded to Outperform from Underperform at Credit Suisse
11/19/21 JPMorgan
Wynn Macau upgraded to Neutral from Underweight at JPMorgan
09/15/21 JPMorgan
Wynn Macau downgraded to Underweight from Overweight at JPMorgan
GXYEF Galaxy Entertainment
$6.14 /

+ (+0.00%)

11/24/21 Credit Suisse
Galaxy Entertainment upgraded to Outperform from Neutral at Credit Suisse
11/19/21 JPMorgan
Galaxy Entertainment upgraded to Overweight from Neutral at JPMorgan
09/15/21 JPMorgan
Galaxy Entertainment downgraded to Neutral from Overweight at JPMorgan
MDEVF Melco International
$1.40 /

+ (+0.00%)

11/24/21 Credit Suisse
Melco International upgraded to Outperform from Underperform at Credit Suisse
11/19/21 JPMorgan
Melco International upgraded to Neutral from Underweight at JPMorgan
09/15/21 JPMorgan
Melco International downgraded to Underweight from Overweight at JPMorgan
MCHVF MGM China
/

+

11/24/21 Credit Suisse
MGM China upgraded to Outperform from Underperform at Credit Suisse
09/15/21 JPMorgan
MGM China downgraded to Neutral from Overweight at JPMorgan
09/13/21 Bernstein
MGM China upgraded to Outperform from Market Perform at Bernstein
MSC Studio City
$6.66 /

-0.57 (-7.88%)

11/24/21 Credit Suisse
Studio City upgraded to Neutral from Underperform at Credit Suisse
PBR Petrobras
$10.48 /

+ (+0.00%)

11/26/21 Morgan Stanley
Morgan Stanley trims Petrobras target to $13.30 after business plan presented
11/16/21 HSBC
Petrobras upgraded to Buy from Hold at HSBC
10/14/21 HSBC
Petrobras downgraded to Hold from Buy at HSBC
10/11/21 Citi
Petrobras transferred with Buy rating at Citi
BP BP
$25.83 /

-1.82 (-6.58%)

11/09/21 Morgan Stanley
BP price target raised to 401 GBp from 388 GBp at Morgan Stanley
10/25/21 TD Securities
BP initiated with a Hold at TD Securities
10/15/21 Berenberg
BP upgraded to Buy from Hold at Berenberg
10/12/21 Morgan Stanley
BP price target raised to 388 GBp from 342 GBp at Morgan Stanley
CVX Chevron
$114.26 /

-2.94 (-2.51%)

11/24/21
Fly Intel: Top five analyst upgrades
11/24/21 RBC Capital
Chevron upgraded to Outperform from Sector Perform at RBC Capital
11/16/21 BofA
Chevron 'in the best shape of the past decade,' says BofA
11/15/21
Fly Intel: Top five analyst upgrades
COP ConocoPhillips
$71.45 /

-3.39 (-4.53%)

11/10/21 Societe Generale
ConocoPhillips downgraded to Hold from Buy at Societe Generale
11/08/21 Argus
ConocoPhillips price target raised to $89 from $66 at Argus
10/26/21 Mizuho
ConocoPhillips price target raised to $99 from $88 at Mizuho
10/21/21 Morgan Stanley
Exxon Mobil, Chevron look poised for 'catch up trade,' says Morgan Stanley
XOM Exxon Mobil
$61.17 /

-2.3 (-3.62%)

11/02/21
Fly Intel: Top five analyst downgrades
11/02/21 Truist
Exxon Mobil downgraded to Sell from Hold at Truist
11/02/21 Truist
Exxon Mobil downgraded to Sell from Hold at Truist
RDS.A Royal Dutch Shell
$42.06 /

-2.16 (-4.88%)

11/17/21 Scotiabank
Royal Dutch Shell upgraded to Outperform at Scotiabank
11/17/21 Scotiabank
Shell Class B upgraded to Outperform from Sector Perform at Scotiabank
11/15/21 UBS
Royal Dutch Shell price target raised to 2,125 GBp from 1,860 GBp at UBS
11/09/21 Morgan Stanley
Royal Dutch Shell price target raised to 2,136 GBp at Morgan Stanley
TOT TotalEnergies
/

+

09/30/21 Citi
Citi downgrades APA Corp. to Neutral on lack of near-term Suriname upside
07/22/21 HSBC
TotalEnergies price target lowered to EUR 41.90 from EUR 49 at HSBC
06/09/21
Fly Intel: Top five analyst initiations
06/09/21 MKM Partners
TotalEnergies initiated with a Buy at MKM Partners
ZM Zoom Video
$220.65 /

+12.41 (+5.96%)

XOM Exxon Mobil
$61.17 /

-2.3 (-3.62%)

UK Ucommune International
/

+

UAL United Airlines
$42.44 /

-4.29 (-9.18%)

TSLA Tesla
$1,082.15 /

-33.85 (-3.03%)

RDS.A Royal Dutch Shell
$42.06 /

-2.16 (-4.88%)

RCL Royal Caribbean
$68.14 /

-10.21 (-13.03%)

QSR Restaurant Brands
$57.95 /

-0.815 (-1.39%)

QGEN Qiagen
$56.42 /

+1.81 (+3.31%)

PTON Peloton
$46.33 /

+2.44 (+5.56%)

PFE Pfizer
$54.12 /

+3.22 (+6.33%)

PDD Pinduoduo
$68.52 /

-12.85 (-15.79%)

OCGN Ocugen
$6.47 /

-0.62 (-8.74%)

NVO Novo Nordisk
$108.19 /

-0.775 (-0.71%)

NCLH Norwegian Cruise Line
$20.22 /

-2.4 (-10.61%)

MSC Studio City
$6.66 /

-0.57 (-7.88%)

MRNA Moderna
$332.27 /

+59 (+21.59%)

MRK Merck
$78.24 /

-4.06 (-4.93%)

MLCO Melco Resorts & Entertainment
$10.39 /

-1.225 (-10.55%)

HUBS HubSpot
$806.16 /

+3.9899 (+0.50%)

DAL Delta Air Lines
$36.20 /

-3.48 (-8.77%)

CVX Chevron
$114.26 /

-2.94 (-2.51%)

COP ConocoPhillips
$71.45 /

-3.39 (-4.53%)

CCL Carnival
$17.98 /

-2.175 (-10.79%)

CANF Can-Fite BioPharma
$1.23 /

+0.05 (+4.24%)

BP BP
$25.83 /

-1.82 (-6.58%)

BNTX BioNTech
$353.00 /

+47.71 (+15.63%)

BABA Alibaba
$133.30 /

-3.32 (-2.43%)

AMZN Amazon.com
$3,509.00 /

-70.75 (-1.98%)

AAPL Apple
$157.52 /

-4.47 (-2.76%)

AAL American Airlines
$17.49 /

-1.97 (-10.12%)

  • 16
    Nov
  • 01
    Nov
  • 05
    Aug
  • 30
    Jun
  • 05
    Mar
  • 01
    Mar
  • 23
    Feb
  • 13
    Jan
ZM Zoom Video
$220.65 /

+12.41 (+5.96%)

XOM Exxon Mobil
$61.17 /

-2.3 (-3.62%)

UAL United Airlines
$42.44 /

-4.29 (-9.18%)

TSLA Tesla
$1,082.15 /

-33.85 (-3.03%)

TOT TotalEnergies
/

+

RDS.A Royal Dutch Shell
$42.06 /

-2.16 (-4.88%)

RCL Royal Caribbean
$68.14 /

-10.21 (-13.03%)

QSR Restaurant Brands
$57.95 /

-0.815 (-1.39%)

PTON Peloton
$46.33 /

+2.44 (+5.56%)

PFE Pfizer
$54.12 /

+3.22 (+6.33%)

PDD Pinduoduo
$68.52 /

-12.85 (-15.79%)

PBR Petrobras
$10.48 /

+ (+0.00%)

OCGN Ocugen
$6.47 /

-0.62 (-8.74%)

NCLH Norwegian Cruise Line
$20.22 /

-2.4 (-10.61%)

MRNA Moderna
$332.27 /

+59 (+21.59%)

MRK Merck
$78.24 /

-4.06 (-4.93%)

MLCO Melco Resorts & Entertainment
$10.39 /

-1.225 (-10.55%)

DIDI Didi
$7.87 /

-0.24 (-2.96%)

DAL Delta Air Lines
$36.20 /

-3.48 (-8.77%)

CVX Chevron
$114.26 /

-2.94 (-2.51%)

CCL Carnival
$17.98 /

-2.175 (-10.79%)

BP BP
$25.83 /

-1.82 (-6.58%)

BNTX BioNTech
$353.00 /

+47.71 (+15.63%)

BABA Alibaba
$133.30 /

-3.32 (-2.43%)

AMZN Amazon.com
$3,509.00 /

-70.75 (-1.98%)

AAPL Apple
$157.52 /

-4.47 (-2.76%)

AAL American Airlines
$17.49 /

-1.97 (-10.12%)

ZM Zoom Video
$220.65 /

+12.41 (+5.96%)

UAL United Airlines
$42.44 /

-4.29 (-9.18%)

TSLA Tesla
$1,082.15 /

-33.85 (-3.03%)

SCHYY Sands China
$26.54 /

+0.84 (+3.27%)

RCL Royal Caribbean
$68.14 /

-10.21 (-13.03%)

QSR Restaurant Brands
$57.95 /

-0.815 (-1.39%)

QGEN Qiagen
$56.42 /

+1.81 (+3.31%)

PTON Peloton
$46.33 /

+2.44 (+5.56%)

PDD Pinduoduo
$68.52 /

-12.85 (-15.79%)

OCGN Ocugen
$6.47 /

-0.62 (-8.74%)

NVO Novo Nordisk
$108.19 /

-0.775 (-0.71%)

NCLH Norwegian Cruise Line
$20.22 /

-2.4 (-10.61%)

MRNA Moderna
$332.27 /

+59 (+21.59%)

MRK Merck
$78.24 /

-4.06 (-4.93%)

MLCO Melco Resorts & Entertainment
$10.39 /

-1.225 (-10.55%)

LIAN LianBio
$16.06 /

+0.49 (+3.15%)

HUBS HubSpot
$806.16 /

+3.9899 (+0.50%)

DIDI Didi
$7.87 /

-0.24 (-2.96%)

DAL Delta Air Lines
$36.20 /

-3.48 (-8.77%)

COP ConocoPhillips
$71.45 /

-3.39 (-4.53%)

CCL Carnival
$17.98 /

-2.175 (-10.79%)

BP BP
$25.83 /

-1.82 (-6.58%)

BABA Alibaba
$133.30 /

-3.32 (-2.43%)

AMZN Amazon.com
$3,509.00 /

-70.75 (-1.98%)

AAPL Apple
$157.52 /

-4.47 (-2.76%)

AAL American Airlines
$17.49 /

-1.97 (-10.12%)

ZM Zoom Video
$220.65 /

+12.41 (+5.96%)

XOM Exxon Mobil
$61.17 /

-2.3 (-3.62%)

UAL United Airlines
$42.44 /

-4.29 (-9.18%)

TSLA Tesla
$1,082.15 /

-33.85 (-3.03%)

TOT TotalEnergies
/

+

RCL Royal Caribbean
$68.14 /

-10.21 (-13.03%)

PTON Peloton
$46.33 /

+2.44 (+5.56%)

PFE Pfizer
$54.12 /

+3.22 (+6.33%)

PDD Pinduoduo
$68.52 /

-12.85 (-15.79%)

PBR Petrobras
$10.48 /

+ (+0.00%)

OCGN Ocugen
$6.47 /

-0.62 (-8.74%)

NCLH Norwegian Cruise Line
$20.22 /

-2.4 (-10.61%)

MRNA Moderna
$332.27 /

+59 (+21.59%)

MRK Merck
$78.24 /

-4.06 (-4.93%)

MLCO Melco Resorts & Entertainment
$10.39 /

-1.225 (-10.55%)

DIDI Didi
$7.87 /

-0.24 (-2.96%)

DAL Delta Air Lines
$36.20 /

-3.48 (-8.77%)

CVX Chevron
$114.26 /

-2.94 (-2.51%)

COP ConocoPhillips
$71.45 /

-3.39 (-4.53%)

CCL Carnival
$17.98 /

-2.175 (-10.79%)

BP BP
$25.83 /

-1.82 (-6.58%)

BNTX BioNTech
$353.00 /

+47.71 (+15.63%)

BABA Alibaba
$133.30 /

-3.32 (-2.43%)

AMZN Amazon.com
$3,509.00 /

-70.75 (-1.98%)

AAPL Apple
$157.52 /

-4.47 (-2.76%)

AAL American Airlines
$17.49 /

-1.97 (-10.12%)

AAPL Apple
$157.52 /

-4.47 (-2.76%)

Hot Stocks
Gilead, Merck temporarily paused Phase 2 islatravir-lenacapavir trial enrollment » 09:34
11/26/21
11/26
09:34
11/26/21
09:34
GILD

Gilead

$70.10 /

-0.54 (-0.76%)

, MRK

Merck

$82.32 /

-0.48 (-0.58%)

On November 23, Gilead…

On November 23, Gilead Sciences (GILD) and Merck (MRK) announced that they are temporarily pausing enrollment in the Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. "This temporary pause has been implemented out of an abundance of caution, to allow the companies to consider potential protocol adjustments to the trial in light of Merck's announcement on November 18 regarding the decision to stop dosing in the Phase 2 IMAGINE-DR clinical trial evaluating the once-weekly combination of MK-8507 and islatravir. The companies remain optimistic about the future potential of the islatravir and lenacapavir combination regimen to provide a once-weekly oral therapy option for people living with HIV. Participants currently enrolled in this trial will continue to receive the study drug and be monitored per the current protocol. Clinical investigators have been informed of this action and will be notified as soon as any potential protocol adjustments are made. Gilead and Merck remain committed to the collaboration to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead's investigational capsid inhibitor, lenacapavir, and Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, as we work to develop new treatment options to address the unmet needs for people living with HIV," the companies stated. Reference Link

ShowHide Related Items >><<
MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

Hot Stocks
Merck drops 4% after Covid pill efficacy drops in larger dataset » 09:18
11/26/21
11/26
09:18
11/26/21
09:18
MRK

Merck

$82.32 /

-0.48 (-0.58%)

, PFE

Pfizer

$50.90 /

-0.195 (-0.38%)

Shares of Merck (MRK) are…

Shares of Merck (MRK) are falling after the company provided an update on molnupiravir, its investigational oral antiviral medicine for Covid-19. Data are now available from all of the enrolled 1433 participants. In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group to 6.8% in the molnupiravir group, for an absolute risk reduction of 3.0% and a relative risk reduction of 30%. Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis, Merck and partner Ridgeback Biotherapeutics said in a statement. The relative risk reduction of 30% is down from the 48% the companies reported previously for molnupiravir. Shares of Merck are down 4% to $78.73 in premarket trading following the data while Pfizer, which is also developing a Covid antiviral treatment, is up 6% to $54.10.

ShowHide Related Items >><<
PFE Pfizer
$50.90 /

-0.195 (-0.38%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
PFE Pfizer
$50.90 /

-0.195 (-0.38%)

11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
11/26/21 Mizuho
Pfizer data on vupanorsen is mixed, says Mizuho
11/24/21 Truist
Pfizer price target raised to $58 from $43 at Truist
11/24/21 Oppenheimer
Enanta price target raised to $73 from $55 at Oppenheimer
PFE Pfizer
$50.90 /

-0.195 (-0.38%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

Hot Stocks
FDA posts briefing documents for meeting to discuss EUA for Merck's molnupiravir » 09:17
11/26/21
11/26
09:17
11/26/21
09:17
MRK

Merck

$82.32 /

-0.48 (-0.58%)

The FDA has posted…

The FDA has posted Advisory Committee briefing documents to summarize the data submitted by Merck and Ridgeback Biotherapeutics to support the Emergency Use Authorization of molnupiravir for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death, ahead of the Antimicrobial Drugs Advisory Committee Meeting to be held on November 30. Currently three antivirals monoclonal antibodies, or mAbs, are authorized for the treatment of mild-to-moderate COVID-19 in individuals who are at high risk for progression to severe COVID-19, but these products all require intravenous or subcutaneous injection for administration, noted the FDA. Molnupiravir is an oral prodrug with antiviral activity against SARS-CoV-2. The FDA is asking the Advisory Committee to discuss the available data regarding the known and potential benefits and the known and potential risks of MOV to support the proposed authorized use and is seeking advice from the Committee regarding the population for authorized use. "The Agency's current assessment is that MOV should not be authorized for initiation of treatment in hospitalized patients because benefit of treatment with MOV was not observed in participants already hospitalized due to COVID-19. However, should a patient require hospitalization after starting treatment with MOV, the patient may complete the full 5-day treatment course at the healthcare provider's discretion," the briefing documents state. Additional considerations regarding the patient population for authorized use include, but are not limited to, how "high risk" is defined for progression to severe COVID-19 and whether SARS-CoV-2 vaccination status should be taken into consideration when making a decision about the use of molnupiravir, the FDA said. Reference Link

ShowHide Related Items >><<
MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

On The Fly
Fly Intel: Pre-market Movers » 09:06
11/26/21
11/26
09:06
11/26/21
09:06
PFE

Pfizer

$50.90 /

-0.195 (-0.38%)

, BNTX

BioNTech

$305.29 /

-3.91 (-1.26%)

, MRNA

Moderna

$273.48 /

-2.9 (-1.05%)

, NVAX

Novavax

$200.12 /

-0.695 (-0.35%)

, VIR

Vir Biotechnology

$32.02 /

+1 (+3.22%)

, REGN

Regeneron

$648.41 /

-0.2 (-0.03%)

, MRK

Merck

$82.32 /

-0.48 (-0.58%)

, PDD

Pinduoduo

$81.37 /

+2 (+2.52%)

, OCGN

Ocugen

$7.09 /

-0.215 (-2.94%)

, ZM

Zoom Video

$208.20 /

+1.275 (+0.62%)

, PTON

Peloton

$43.91 /

+0.93 (+2.16%)

, DASH

DoorDash

$184.85 /

+0.81 (+0.44%)

, NFLX

Netflix

$657.85 /

+3.55 (+0.54%)

, DOCU

DocuSign

$243.38 /

+0.74 (+0.30%)

Check out this morning's…

ShowHide Related Items >><<
ZM Zoom Video
$208.20 /

+1.275 (+0.62%)

VIR Vir Biotechnology
$32.02 /

+1 (+3.22%)

REGN Regeneron
$648.41 /

-0.2 (-0.03%)

PTON Peloton
$43.91 /

+0.93 (+2.16%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

PDD Pinduoduo
$81.37 /

+2 (+2.52%)

OCGN Ocugen
$7.09 /

-0.215 (-2.94%)

NVAX Novavax
$200.12 /

-0.695 (-0.35%)

NFLX Netflix
$657.85 /

+3.55 (+0.54%)

MRNA Moderna
$273.48 /

-2.9 (-1.05%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

DOCU DocuSign
$243.38 /

+0.74 (+0.30%)

DASH DoorDash
$184.85 /

+0.81 (+0.44%)

BNTX BioNTech
$305.29 /

-3.91 (-1.26%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
11/26/21 Mizuho
Pfizer data on vupanorsen is mixed, says Mizuho
11/24/21 Truist
Pfizer price target raised to $58 from $43 at Truist
11/24/21 Oppenheimer
Enanta price target raised to $73 from $55 at Oppenheimer
BNTX BioNTech
$305.29 /

-3.91 (-1.26%)

11/10/21
Fly Intel: Top five analyst upgrades
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/10/21 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
10/22/21
Fly Intel: Top five analyst initiations
MRNA Moderna
$273.48 /

-2.9 (-1.05%)

11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
11/08/21 Wolfe Research
Moderna initiated with an Outperform at Wolfe Research
NVAX Novavax
$200.12 /

-0.695 (-0.35%)

11/08/21 B. Riley
Novavax not a one-trick pony, says B. Riley
10/20/21 Cantor Fitzgerald
Novavax submissions will 'dissipate the current debate,' says Cantor Fitzgerald
09/08/21 Cantor Fitzgerald
Novavax combo vaccine could have 'differentiating' value, says Cantor Fitzgerald
08/30/21 B. Riley
Novavax is leader in making Covid-flu combination candidate, says B. Riley
VIR Vir Biotechnology
$32.02 /

+1 (+3.22%)

11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
10/25/21 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
REGN Regeneron
$648.41 /

-0.2 (-0.03%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
11/05/21
Fly Intel: Top five analyst downgrades
MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
PDD Pinduoduo
$81.37 /

+2 (+2.52%)

11/02/21 Barclays
Pinduoduo initiated with Equal Weight, $103 target at Barclays
11/02/21 Barclays
Pinduoduo initiated with an Equal Weight at Barclays
08/25/21 BofA
Pinduoduo price target raised to $148 from $143 at BofA
08/25/21 Benchmark
Pinduoduo price target lowered to $156 from $176 at Benchmark
OCGN Ocugen
$7.09 /

-0.215 (-2.94%)

07/26/21 Noble Capital
Ocugen initiated with an Outperform at Noble Capital
07/06/21 Roth Capital
Covaxin data continue to meet FDA efficacy threshold, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
ZM Zoom Video
$208.20 /

+1.275 (+0.62%)

11/23/21
Fly Intel: Top five analyst downgrades
11/23/21 BofA
Zoom Video downgraded to Neutral from Buy at BofA
11/23/21 Wells Fargo
Zoom Video price target lowered to $245 from $275 at Wells Fargo
11/23/21 Evercore ISI
Zoom Video price target lowered to $235 from $255 at Evercore ISI
PTON Peloton
$43.91 /

+0.93 (+2.16%)

11/16/21 Baird
Baird adds Peloton as 'Fresh Pick,' says capital raise removes overhang
11/16/21 BMO Capital
Peloton 'backpedaling again' with $1B offering, says BMO Capital
11/11/21 RBC Capital
Affirm price target raised to $175 from $130 at RBC Capital
11/09/21 JMP Securities
Peloton should be bought on weakness, says JMP Securities
DASH DoorDash
$184.85 /

+0.81 (+0.44%)

11/22/21 KGI Securities
DoorDash upgraded to Outperform from Neutral at KGI Securities
11/18/21 Morgan Stanley
Uber One subscription offering well positioned versus peers, says Morgan Stanley
11/11/21 DA Davidson
DoorDash price target raised to $210 from $158 at DA Davidson
11/11/21 Susquehanna
DoorDash price target raised to $260 from $220 at Susquehanna
NFLX Netflix
$657.85 /

+3.55 (+0.54%)

11/22/21 Wells Fargo
Disney price target lowered to $196 from $203 at Wells Fargo
11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
11/15/21 KeyBanc
Netflix price target raised to $725 from $690 at KeyBanc
11/15/21 JPMorgan
Netflix entering 'strongest content quarter ever,' says JPMorgan
DOCU DocuSign
$243.38 /

+0.74 (+0.30%)

10/06/21
DocuSign participates in a conference call with Benchmark
09/03/21 Evercore ISI
DocuSign price target raised to $320 from $285 at Evercore ISI
09/03/21 Needham
DocuSign price target raised to $340 from $275 at Needham
ZM Zoom Video
$208.20 /

+1.275 (+0.62%)

VIR Vir Biotechnology
$32.02 /

+1 (+3.22%)

REGN Regeneron
$648.41 /

-0.2 (-0.03%)

PTON Peloton
$43.91 /

+0.93 (+2.16%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

PDD Pinduoduo
$81.37 /

+2 (+2.52%)

OCGN Ocugen
$7.09 /

-0.215 (-2.94%)

NVAX Novavax
$200.12 /

-0.695 (-0.35%)

NFLX Netflix
$657.85 /

+3.55 (+0.54%)

MRNA Moderna
$273.48 /

-2.9 (-1.05%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

DOCU DocuSign
$243.38 /

+0.74 (+0.30%)

DASH DoorDash
$184.85 /

+0.81 (+0.44%)

BNTX BioNTech
$305.29 /

-3.91 (-1.26%)

  • 16
    Nov
  • 19
    Aug
  • 20
    May
  • 13
    Jan
  • 09
    Dec
ZM Zoom Video
$208.20 /

+1.275 (+0.62%)

VIR Vir Biotechnology
$32.02 /

+1 (+3.22%)

PTON Peloton
$43.91 /

+0.93 (+2.16%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

PDD Pinduoduo
$81.37 /

+2 (+2.52%)

OCGN Ocugen
$7.09 /

-0.215 (-2.94%)

NVAX Novavax
$200.12 /

-0.695 (-0.35%)

NFLX Netflix
$657.85 /

+3.55 (+0.54%)

MRNA Moderna
$273.48 /

-2.9 (-1.05%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

DOCU DocuSign
$243.38 /

+0.74 (+0.30%)

DASH DoorDash
$184.85 /

+0.81 (+0.44%)

BNTX BioNTech
$305.29 /

-3.91 (-1.26%)

ZM Zoom Video
$208.20 /

+1.275 (+0.62%)

VIR Vir Biotechnology
$32.02 /

+1 (+3.22%)

REGN Regeneron
$648.41 /

-0.2 (-0.03%)

PTON Peloton
$43.91 /

+0.93 (+2.16%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

PDD Pinduoduo
$81.37 /

+2 (+2.52%)

OCGN Ocugen
$7.09 /

-0.215 (-2.94%)

NVAX Novavax
$200.12 /

-0.695 (-0.35%)

NFLX Netflix
$657.85 /

+3.55 (+0.54%)

MRNA Moderna
$273.48 /

-2.9 (-1.05%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

DOCU DocuSign
$243.38 /

+0.74 (+0.30%)

DASH DoorDash
$184.85 /

+0.81 (+0.44%)

BNTX BioNTech
$305.29 /

-3.91 (-1.26%)

ZM Zoom Video
$208.20 /

+1.275 (+0.62%)

REGN Regeneron
$648.41 /

-0.2 (-0.03%)

PTON Peloton
$43.91 /

+0.93 (+2.16%)

PFE Pfizer
$50.90 /

-0.195 (-0.38%)

PDD Pinduoduo
$81.37 /

+2 (+2.52%)

OCGN Ocugen
$7.09 /

-0.215 (-2.94%)

NVAX Novavax
$200.12 /

-0.695 (-0.35%)

NFLX Netflix
$657.85 /

+3.55 (+0.54%)

MRNA Moderna
$273.48 /

-2.9 (-1.05%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

DOCU DocuSign
$243.38 /

+0.74 (+0.30%)

DASH DoorDash
$184.85 /

+0.81 (+0.44%)

BNTX BioNTech
$305.29 /

-3.91 (-1.26%)

Hot Stocks
Merck, Ridgeback provide update on results from MOVe-OUT study of molnupiravir » 06:48
11/26/21
11/26
06:48
11/26/21
06:48
MRK

Merck

$82.32 /

-0.48 (-0.58%)

Merck and Ridgeback…

Merck and Ridgeback Biotherapeutics provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants. In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group to 6.8% in the molnupiravir group, for an absolute risk reduction of 3.0% and a relative risk reduction of 30%. Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis. Based on the study design, the definitive evaluation of efficacy was considered complete at the planned interim analysis, when the statistical criterion for success was met and enrollment in the study was discontinued at the recommendation of the external Data Monitoring Committee and agreed to by the U.S. FDA. As previously reported, at the planned interim analysis, molnupiravir significantly reduced the risk of hospitalization or death from 14.1% in the placebo group to 7.3% in the molnupiravir group, for a relative risk reduction of 48%. The interim analysis and the additional analyses support the efficacy and overall favorable benefit-risk assessment of molnupiravir for the treatment of mild to moderate COVID-19 in adults at high risk for disease progression. Merck has shared these additional analyses with the FDA and they will be presented to the FDA's Antimicrobial Drugs Advisory Committee on Nov. 30th.

ShowHide Related Items >><<
MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

Wednesday
On The Fly
Fly Intel: After-Hours Movers » 18:34
11/24/21
11/24
18:34
11/24/21
18:34
AURA

Aura Biosciences

$19.77 /

+1.94 (+10.88%)

, CARS

Cars.com

$13.32 /

+0.02 (+0.15%)

, BRKR

Bruker

$77.35 /

-0.31 (-0.40%)

, NVEE

NV5 Global

$115.50 /

-0.05 (-0.04%)

, KAR

KAR Auction

$14.96 /

-0.1 (-0.66%)

, CANO

Cano Health

$9.32 /

+0.12 (+1.30%)

, SELB

Selecta Biosciences

$3.18 /

+0.01 (+0.32%)

, AVIR

Atea Pharmaceuticals

$7.70 /

+0.005 (+0.07%)

Check out this evening's…

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.18 /

+0.01 (+0.32%)

NVEE NV5 Global
$115.50 /

-0.05 (-0.04%)

KAR KAR Auction
$14.96 /

-0.1 (-0.66%)

CARS Cars.com
$13.32 /

+0.02 (+0.15%)

CANO Cano Health
$9.32 /

+0.12 (+1.30%)

BRKR Bruker
$77.35 /

-0.31 (-0.40%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AURA Aura Biosciences
$19.77 /

+1.94 (+10.88%)

AURA Aura Biosciences
$19.77 /

+1.94 (+10.88%)

11/23/21 SVB Leerink
Aura Biosciences initiated with an Outperform at SVB Leerink
11/23/21 BTIG
Aura Biosciences initiated with a Buy at BTIG
11/23/21 Evercore ISI
Evercore starts Aura Biosciences at Outperform with $35 price target
11/23/21 Cowen
Aura Biosciences initiated with an Outperform at Cowen
CARS Cars.com
$13.32 /

+0.02 (+0.15%)

08/27/21
Fly Intel: Top five analyst initiations
08/27/21 Truist
Cars.com initiated with a Buy at Truist on 'attractive' valuation
08/27/21 Truist
Cars.com initiated with a Buy at Truist
05/10/21 Barrington
Cars.com price target raised to $25 from $16 at Barrington
BRKR Bruker
$77.35 /

-0.31 (-0.40%)

10/14/21 Cowen
Bruker coverage transferred at Cowen
08/03/21 Wells Fargo
Bruker price target raised to $85 from $70 at Wells Fargo
08/03/21 Citi
Bruker price target raised to $85 from $75 at Citi
06/15/21 Cleveland Research
Bruker upgraded to Buy from Neutral at Cleveland Research
NVEE NV5 Global
$115.50 /

-0.05 (-0.04%)

03/29/21 Roth Capital
Roth Capital positive on NV5 acquisition of Geodynamics
03/15/21 Baird
NV5 Global initiated with an Outperform at Baird
01/13/21 Roth Capital
NV5 Global price target raised to $136 from $82 at Roth Capital
KAR KAR Auction
$14.96 /

-0.1 (-0.66%)

08/04/21 JPMorgan
ACV Auctions upgraded to Overweight from Neutral at JPMorgan
05/24/21 JPMorgan
KAR Auction price target raised to $24 from $21 at JPMorgan
05/21/21 BofA
KAR Auction upgraded to Buy from Underperform at BofA
02/18/21
Fly Intel: Top five analyst downgrades
CANO Cano Health
$9.32 /

+0.12 (+1.30%)

11/10/21 Piper Sandler
Cano Health price target raised to $13 from $11 at Piper Sandler
10/20/21 Jefferies
Cano Health initiated with a Buy at Jefferies
10/19/21 Piper Sandler
Cano Health initiated with a Neutral at Piper Sandler
10/01/21 Wolfe Research
Wolfe Research starts Cano Health at Outperform with $19 price target
SELB Selecta Biosciences
$3.18 /

+0.01 (+0.32%)

07/22/21 Cantor Fitzgerald
Incorrect headline could be cause of Selecta weakness, says Cantor Fitzgerald
06/14/21 BTIG
Selecta Biosciences initiated with a Buy at BTIG
04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

11/18/21
Fly Intel: Top five analyst downgrades
11/18/21 SVB Leerink
Atea Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
10/20/21 SVB Leerink
Atea Pharmaceuticals price target lowered to $20 from $60 at SVB Leerink
10/20/21 JPMorgan
JPMorgan downgrades Atea on 'challenging path forward' in Covid
SELB Selecta Biosciences
$3.18 /

+0.01 (+0.32%)

NVEE NV5 Global
$115.50 /

-0.05 (-0.04%)

KAR KAR Auction
$14.96 /

-0.1 (-0.66%)

CARS Cars.com
$13.32 /

+0.02 (+0.15%)

CANO Cano Health
$9.32 /

+0.12 (+1.30%)

BRKR Bruker
$77.35 /

-0.31 (-0.40%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AURA Aura Biosciences
$19.77 /

+1.94 (+10.88%)

  • 29
    Oct
  • 11
    Mar
AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

KAR KAR Auction
$14.96 /

-0.1 (-0.66%)

CANO Cano Health
$9.32 /

+0.12 (+1.30%)

BRKR Bruker
$77.35 /

-0.31 (-0.40%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AURA Aura Biosciences
$19.77 /

+1.94 (+10.88%)

CANO Cano Health
$9.32 /

+0.12 (+1.30%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

Syndicate
Atea Pharmaceuticals files $200M mixed securities shelf  16:09
11/24/21
11/24
16:09
11/24/21
16:09
AVIR

Atea Pharmaceuticals

$7.70 /

+0.005 (+0.07%)

 
ShowHide Related Items >><<
AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

11/18/21
Fly Intel: Top five analyst downgrades
11/18/21 SVB Leerink
Atea Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
10/20/21 SVB Leerink
Atea Pharmaceuticals price target lowered to $20 from $60 at SVB Leerink
10/20/21 JPMorgan
JPMorgan downgrades Atea on 'challenging path forward' in Covid
AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

AVIR Atea Pharmaceuticals
$7.70 /

+0.005 (+0.07%)

Recommendations
Merck price target raised to $95 from $92 at Truist » 08:55
11/24/21
11/24
08:55
11/24/21
08:55
MRK

Merck

$82.80 /

+1.12 (+1.37%)

Truist analyst Robyn…

Truist analyst Robyn Karnauskas raised the firm's price target on Merck to $95 from $92 and keeps a Buy rating on the shares as part of a broader research note on Major Pharma updating modeled forecasts for the group. The analyst also raises her FY21 EPS view on the company to $5.98 from $5.47 and FY22 view to $7.58 from $6.40.

ShowHide Related Items >><<
MRK Merck
$82.80 /

+1.12 (+1.37%)

MRK Merck
$82.80 /

+1.12 (+1.37%)

11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
MRK Merck
$82.80 /

+1.12 (+1.37%)

MRK Merck
$82.80 /

+1.12 (+1.37%)

MRK Merck
$82.80 /

+1.12 (+1.37%)

MRK Merck
$82.80 /

+1.12 (+1.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.